EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials

Xavier Choderlos de Laclos, Séverine Risbourg, Bernadette Brennan, François Bertucci, Nathalie Gaspar, Hans Gelderblom, Douglas S Hawkins, Katherine Janeway, Heribert Juergens, Bernd Kasper, Mark D Krailo, Marie Cécile Le Deley und 9 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114229 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Xavier Choderlos de Laclos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Eugène Marquis Centre, Avenue de la Bataille Flandres-Dunkerque, Rennes, France. Electronic address: x.choderlos-de-laclos@renne…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Sarcoma, Ewing, Busulfan, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Stiftung Deutsche Krebshilfe, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationSarcoma, EwingBusulfanAntineoplastic Combined Chemotherapy ProtocolsTransplantation, AutologousMelphalanHumansChildAdolescentYoung AdultMaleFemaleAge FactorsAdultEtoposideBone NeoplasmsVincristineChild, PreschoolIfosfamideTreatment Outcome

Stichwörter der Autor:innen

Autologous hematopoietic stem cells transplantationEwing sarcoma (ES)High dose chemotherapySafety

Substanzen

BusulfanMelphalanEtoposideVincristineIfosfamide

Autor:innen und Institutionen

  • Oncology Department, Eugène Marquis Centre, Avenue de la Bataille Flandres-Dunkerque, Rennes, France. Electronic address: x.choderlos-de-laclos@rennes.unicancer.fr.
  • Methodology and Biostatistics Unit, Oscar Lambret Centre, 3 Rue Frédéric Combemale, Lille, France. Electronic address: s-risbourg@o-lambret.fr.
  • Department of paediatric oncology, Royal Manchester Children's Hospital, Manchester, UK. Electronic address: Bernadette.Brennan@mft.nhs.uk.
  • Department of Medical Oncology, Paoli-Calmettes Institute, Aix-Marseille Université, 232 Boulevard de Sainte-Marguerite, Marseille, France. Electronic address: BERTUCCIF@ipc.unicancer.fr.
  • Department of Oncology for Child and adolescent, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France. Electronic address: Nathalie.GASPAR@gustaveroussy.fr.
  • Department of Medical Oncology, Leiden University Medical Center, The Netherlands. Electronic address: a.j.gelderblom@lumc.nl.

Förderung

  • NCI NIH HHS
  • Stiftung Deutsche Krebshilfe
  • Bundesministerium für Bildung und Forschung
  • Institut National Du Cancer
  • Cancer Research UK
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Cancer Institute
  • Ligue Contre le Cancer

Zitieren

APA

Choderlos de Laclos, X., Risbourg, S., Brennan, B., Bertucci, F., Gaspar, N., Gelderblom, H., Hawkins, D. S., Janeway, K., Juergens, H., Kasper, B., Krailo, M. D., Cécile Le Deley, M., Marec-Bérard, P., McCabe, M. G., Metzler, M., Ranft, A., Strauss, S., Tabone, M. D., Windsor, R., …, & Gandemer, V. (2024). Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114229

Vancouver

Choderlos de Laclos X, Risbourg S, Brennan B, Bertucci F, Gaspar N, Gelderblom H, et al. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114229

BibTeX
@article{ChoderlosdeLaclos2024,
  author = {Choderlos de Laclos, Xavier and Risbourg, Séverine and Brennan, Bernadette and Bertucci, François and Gaspar, Nathalie and Gelderblom, Hans and Hawkins, Douglas S and Janeway, Katherine and Juergens, Heribert and Kasper, Bernd and Krailo, Mark D and Cécile Le Deley, Marie and Marec-Bérard, Perrine and McCabe, Martin G and Metzler, Markus and Ranft, Andreas and Strauss, Sandra and Tabone, Marie-Dominique and Windsor, Rachael and Dirksen, Uta and Gandemer, Virginie},
  title = {Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114229}
}
Kostenlos starten →